Furthermore, elevated EC-PY397-FAK expression levels are strongly correlated with advanced clinical parameters of breast cancer and poor treatment response and independently predict unfavorable five-year recurrence-free survival, which highlights the need to assess the role of FAK inhibitors in optimizing treatments and improve the response to various strategies [159]. The gene discussed is PTK2; the disease is breast cancer.